Get the Stockscreener App
55.20
0.25%
0.14
After Hours:
55.20
Anaptysbio Inc stock is traded at $55.20, with a volume of 868.84K.
It is up +0.25% in the last 24 hours and down -6.42% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$55.06
Open:
$55.76
24h Volume:
868.84K
Relative Volume:
1.49
Market Cap:
$1.63B
Revenue:
$232.39M
Net Income/Loss:
$-26.79M
P/E Ratio:
-51.09
EPS:
-1.0804
Net Cash Flow:
$4.41M
1W Performance:
+2.47%
1M Performance:
-6.42%
6M Performance:
-14.71%
1Y Performance:
+161.86%
1-Day Range:
$53.71
$55.77
1-Week Range:
$53.22
$55.79
52-Week Range:
$20.49
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
55.20 | 1.60B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage By Investing.com - Investing.com Canada
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage - investing.com
ANAB Q2'26 Earnings: EPS estimate is (0.47) USD - TradingView
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) - Yahoo Finance UK
Squarepoint Ops LLC Has $21.90 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. $ANAB Shares Purchased by Hsbc Holdings PLC - MarketBeat
U.S. Earnings Preview: After Market Close Sept. 8 - moomoo.com
Irenic Capital Management LP Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Bank of New York Mellon Corp Makes New $3.81 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Anaptysbio Stock Price Forecast. Should You Buy ANAB? - StockInvest.us
ANAB Q2'26 Earnings: revenue estimate is 8.89M USD - TradingView
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
U.S. Earnings Preview: After Market Close Sept. 1 - Moomoo
AnaptysBio stock rating maintained at Outperform by Wolfe Research - Investing.com Nigeria
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com Australia
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? - Investing.com
Empowered Funds LLC Makes New $13.91 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
1,844,049 Shares in AnaptysBio, Inc. $ANAB Bought by BlackRock Inc. - marketbeat.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio Inc. (ANAB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Palo Alto Investors LP Purchases Shares of 603,489 AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Purchases Shares of 216,949 AnaptysBio, Inc. $ANAB - MarketBeat
Deutsche Bank AG Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Takes Position in AnaptysBio, Inc. $ANAB - MarketBeat
ANAB Maintained by TD Cowen -- Price Target Lowered to $70 - GuruFocus
TD Cowen lowers Anaptysbio stock price target to $70 on FDA review - Investing.com UK
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating - Moomoo
AnaptysBio, Inc. (ANAB) Earnings Preview: The First Full Royalty-Model Quarter Matters More Than the Headline EPS - AlphaStreet
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $70 - Moomoo
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright - MarketBeat
Greenhaven Road Investment Management, L.P.'s AnaptysBio Inc(ANAB) Holding History - GuruFocus
AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup - ChartMill
U.S. Earnings Preview: After Market Close Aug. 18 - Moomoo
US High Growth Tech Stocks To Watch In August 2026 - simplywall.st
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control - Yahoo Finance
Bank of America Corp DE Boosts Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio earnings ahead: First results as royalty company By Investing.com - Investing.com Canada
AnaptysBio earnings ahead: First results as royalty company - Investing.com
AnaptysBio (NASDAQ:ANAB) Shares Pass Above Fifty Day Moving AverageHere's What Happened - MarketBeat
AnaptysBio (ANAB) Holds Steady at $56.09: Key Levels to WatchNew Listing Stocks - vinanet.vn
Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A - Stock Titan
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95 - Moomoo
AnaptysBio Shareholders Back Board, Governance and Incentives - The Globe and Mail
AnaptysBio Announces Results of 2026 Annual Stockholders Meeting Voting - Kalkine Media
AnaptysBio (ANAB) Climbs 4.33% to $57.87 as Biotech Momentum BuildsETF NAV Deviation - vinanet.vn
Is AnaptysBio (ANAB) Undervalued After Its Recent Share Price Swings? - Sahm
Price-Driven Insight from (ANAB) for Rule-Based Strategy - Stock Traders Daily
AnaptysBio (ANAB) Rallies 3.36% as Biotech Momentum Builds Toward Key ResistanceGolden Cross - dars.gov.et
AnaptysBio (ANAB) awards CEO 53,334 performance stock units - Stock Titan
AnaptysBio (NASDAQ: ANAB) awards 16,667 performance stock units to its CMO - Stock Titan
AnaptysBio Inc (ANAB) Stock News Today - TradingKey
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):